Sun Pharma Advanced Research Company Receives Consideration for Preferential Allotment of Warrants

Sun Pharma Advanced Research Company Receives Consideration for Preferential Allotment of Warrants

Sun Pharma Advanced Research Company Receives Consideration for Preferential Allotment of Warrants​

Sun Pharma Advanced Research Company Limited announced the receipt of consideration towards the preferential allotment of warrants. The transaction involves an allottee named Shanghvi Finance Private Limited, solidifying the company's capital structure through the allotment of equity instruments.

On May 19, 2026, the company received funds from Shanghvi Finance Private Limited. This transaction involved the preferential allotment of 3,85,10,000 warrants. The total amount received against these warrants was Rs. 149,99,64,500.

The payment was made through the following bank details:

ParticularsDetails
Allottee NameShanghvi Finance Private Limited
Number of Warrants Allotted3,85,10,000
Amount ReceivedRs. 149,99,64,500
Bank Name and BranchICICI Bank, Mumbai-Nariman Point
Bank Account Number000405006328
Date of ReceiptMay 19, 2026
UTR NumbersICICR42026051900505658, ICICR42026051900505656, ICICR42026051900505659, ICICR42026051900505657

SPARC Stock Price Movement​

On Monday, shares of Sun Pharma Advanced Research Company Limited edged higher, rallying 12.41% to settle at ₹232.99. The stock hit its 52-week high, supported by heavy trading volumes that reached 60.72 million shares.
 

Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.

The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.

Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.

Last edited by a moderator:
Back
Top